MitchellGrossMD

PubMed

• 3 citations
  Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial.
  Jacqueline K. Dawson, Tanya B. Dorff, Creighton T. Tuzon, Judd C. Rice, E T. Schroeder, Christianne J. Lane, Mitchell E. Gross, Christina M. Dieli-Conwright> ;Integrative Cancer Therapies. 2021 Jul 23
• 21 citations
  CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation.
  Noah Trac, Leng-Ying Chen, Ailin Zhang, Chun-Peng Liao, Christopher Poon, Jonathan Wang, Yuta Ando, Johan Joo, Carolina Garri, Keyue Shen, Kian Kani, Mitchell E. Gross...> ;Journal of Controlled Release. 2021 Jan 10
• 30 citations
  Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
  Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek Pinski, David I. Quinn, Olga O. Castellanos, Patrick O. Gilmore, Jean C. Shih> ;Prostate Cancer and Prostatic Diseases. 2021 Mar 1
• 9 citations
  Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).
  Tanya B. Dorff, David I. Quinn, Jacek Pinski, Amir Goldkorn, Sarmad Sadeghi, Denice D. Tsao-Wei, Susan Groshen, Peter Kuhn, Mitchell E. Gross> ;Clinical Genitourinary Cancer. 2019 Aug 1
• 18 citations
  Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA).
  Katherin Patsch, Naim Matasci, Anjana Soundararajan, Patricia M Diaz, David B. Agus, Daniel Ruderman, Mitchell E. Gross> ;BMC Research Notes. 2019 May 15
• 37 citations
  Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
  Shikha Gaur, Mitchell E. Gross, Chun-Peng Liao, Bin Qian, Jean C. Shih> ;The Prostate. 2019 May 1
• 21 citations
  Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis.
  Katrin Tiemann, Carolina Garri, Sang Bok Lee, Paymaneh D. Malihi, Mincheol Park, Ruth M Alvarez, Li Peng Yap, Parag Mallick, Jonathan E. Katz, Mitchell E. Gross, Kian ...> ;Oncogene. 2019 Apr 1
• 37 citations
  Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
  Jelena Belic, Ricarda Graf, Thomas Bauernhofer, Yauheniya Cherkas, Peter Ulz, Julie Waldispuehl-Geigl, Samantha Perakis, Michael Gormley, Jaymala Patel, Weimin Li, Joc...> ;International Journal of Cancer. 2018 Sep 1
• Motor behavior characteristics in various phases of bipolar disorder revealed through biomechanical analysis: Quantitative measures of activity and energy variables du...
  Kang, G. E.,Mickey, B. J.,McInnis, M. G.,Krembs, B. S.,Gross, M. M.> ;Psychiatry Res. 2018 Aug 27
• 8 citations
  Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2).
  Carolina Garri, Shannon M. Howell, Katrin Tiemann, Aleczandria S. Tiffany, Farzad Jalali-Yazdi, Mario M. Alba, Jonathan E. Katz, Terry T. Takahashi, Ralf Landgraf, Mit...> ;Oncotarget. 2018 Jun 8
• 42 citations
  Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
  Chun-Peng Liao, Tzu-Ping Lin, Pei-Chuan Li, Lauren A. Geary, Kevin Chen, Vijaya Pooja Vaikari, Jason Boyang Wu, Chi Hung Lin, Mitchell E. Gross, Jean C. Shih> ;Oncogene. 2018 May 29
• 64 citations
  Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controll...
  Jacqueline K. Dawson, Tanya B. Dorff, E. Todd Schroeder, Christianne J. Lane, Mitchell E. Gross, Christina M. Dieli-Conwright> ;BMC Cancer. 2018 Apr 3
• 16 citations
  Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles
  Christopher Poon, Sampreeti Chowdhuri, Cheng Hsiang Kuo, Yun Fang, Francis J. Alenghat, Danielle Hyatt, Kian Kani, Mitchell E. Gross, Eun Ji Chung> ;ACS Biomaterials Science & Engineering. 2017 Oct 16
• 9 citations
  Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).
  Mitchell E. Gross, Tanya B. Dorff, David I. Quinn, Patricia M Diaz, Olga O. Castellanos, David B. Agus> ;Clinical Genitourinary Cancer. 2017 Jul 14
• 13 citations
  A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation t...
  Jacqueline L. Kiwata, Tanya B. Dorff, E. Todd Schroeder, George J. Salem, Christianne J. Lane, Judd C. Rice, Mitchell E. Gross, Christina M. Dieli-Conwright> ;BMJ Open. 2017 Jul 1
• 4 citations
  Automated analysis of co-localized protein expression in histologic sections of prostate cancer.
  Thomas A. Tennill, Mitchell E. Gross, Hermann B. Frieboes> ;Plos One. 2017 May 26
• 22 citations
  Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.
  Chun-Peng Liao, Leng-Ying Chen, Andrea Luethy, Youngsoo Kim, Kian Kani, A. Robert MacLeod, Mitchell E. Gross> ;Endocrine-Related Cancer. 2017 Apr 1
• 18 citations
  A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients
  Jacqueline L. Kiwata, Tanya B. Dorff, E T. Schroeder, Mitchell E. Gross, Christina M. Dieli-Conwright> ;Prostate Cancer and Prostatic Diseases. 2016 Jun 28
• 17 citations
  Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design
  Willemien van den Bos, Berrend G. Muller, Daniel M. de Bruin, Andre Luis de Castro Abreu, Christian G. Chaussy, Jonathan A. Coleman, Antonio Finelli, Inderbir S. Gill,...> ;Urologic Oncology. 2015 Nov 1
• 3 citations
  Blood-based gene expression profiling in castrate-resistant prostate cancer
  Mitchell E. Gross> ;BMC Medicine. 2015 Sep 14
• 18 citations
  A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progres...
  Osamu Ukimura, Mitchell E. Gross, Andre Luis de Castro Abreu, Raed A. Azhar, Toru Matsugasumi, So Ushijima, Motohiro Kanazawa, Manju Aron, Inderbir S. Gill> ;The Prostate. 2015 Jun 1
• 1 citations
  Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
  Tanya B. Dorff, Mitchell E. Gross> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2015 May 14
• 27 citations
  Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and Progression
  Nitin Patel, Tatsuo Itakura, Shinwu Jeong, Chun-Peng Liao, Pradip Roy-Burman, Ebrahim Zandi, Susan Groshen, Jacek Pinski, Gerhard A. Coetzee, Mitchell E. Gross, M. Eli...> ;Plos One. 2015 Feb 18
• 51 citations
  Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies
  Osamu Ukimura, Arnaud Marien, Suzanne L. Palmer, Arnauld Villers, Manju Aron, Andre Luis de Castro Abreu, Scott Leslie, Sunao Shoji, Toru Matsugasumi, Mitchell E. Gros...> ;World Journal of Urology. 2015 Feb 6
• 40 citations
  Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors.
  Stacy A. Eisenberg, Keiko Kurita, Megan Taylor-Ford, David B. Agus, Mitchell E. Gross, Beth E. Meyerowitz> ;Psycho-Oncology. 2015 Feb 1
• Join now to see all

Journal Articles

• Role of AUUU sequences in stabilization of granuclocyte-macrophage colony-stimulating factor RNA in stimulated cells.  
  Akashi M., Shaw G., Gross M., Saito M., Koeffler H.P, Blood. 78:2005-12.
• Lack of effect of clinical research protocol participation on morbidity measures in HIV-infected children.  
  Gross M.E., Smith E.O., Kline M.W, Ped. Infect Dis.J. 12:157-8
• Antimicrobial activities of beta-lactam antibiotics and gentamycin against penicillin-susceptible and penicillin-resistant pneumococci.  
  Gross M.E., Giron K.P., Septimus J.D., Mason E.O., Musher D.M, Antimicro Agents Chemo. 39:1166-8
• In vitro antimicrobial effect against Steptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or l-oflaxacin.  
  Giron K.P., Gross M.E., Musher D.M., Williams T.W. Jr, Antimicro. Agents Chemo. 39:2798-2800.
• A transcriptional corepressor of Stat1 with an essential LXXLL signature motif.  
  Liu, B, Gross, M, ten Hoeve, J., Shuai, K, Proc. Natl. Acad. Sci. USA 98: 3203-3207
• Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells.  
  Gross, M., Liu, B., Tan, J-a., French, F.S., Carey, M., Shuai, K, Oncogene, 20: 3880-7
• PIASy-mediated repression of the androgen receptor is independent of sumoylation.  
  Gross, M., Yang, R., Top, I., Gasper, C., Shuai, K, Oncogene. 23:3059-66
• Protein Partners of C/EBPe.  
  Chih, D.Y., Park, D.J., Gross, M., Idos, G., Vuong, P.T., Hirama,T., Chumakov, A.M., Said, J., Koeffler, H.P, Exp Hematol. 32:1173-81
• Raloxifene, an ER-β targeted therapy, inhibits androgen independent prostate cancer growth: results from preclinical studies and a Phase II clinical trial.  
  Shazer, R., Galkin,A., Aronson, N., Nguyen, K., Cinman, N., Natale, R., Gross, M., Green, L., Bender, L., Holden, S., Kaplan, S., Agus, D.B, BJU Int. 97:691-7.
• Phase II evaluation of cilengitide in asymptomatic patients with androgen-indpendent prostate cancer: scientific rationale and study design.  
  Beekman, K.W., Colevas, A.D., Cooney, K., Dipaola, R., Dunn, R.L., Gross, M., Keller, E.T., Ryan, C.J., Smith, D., Hussain, Clin. Genitourin. Cancer 4:299-302
• Review of Metastasectomy for Isolated Bilateral Adrenal Metastases in Hormone-refractory Prostate Cancer.  
  Gross, M, Clin. Adv.Hemat. Oncol. 4:756-7
• Beta-2-microglobulin is an Androgen-regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer.  
  Gross, M., Top, I., Laux, I., Katz, J., Curran, J., Tindell, C., Agus, D, Clin. Cancer Res., 13:1979-1986
• Defining the activity of second-line regimens in taxane refractory hormone refractory prostate cancer patients refractory to taxanes: a randomized phase II study of ix...  
  Rosenberg, J., Weinberb, V., Gross, M., Wilding, G., Hussain, M., Kelly, W.K., Hutcheon, D., Small, E, Cancer, 110:556-63
• A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.  
  Gross, M., Higano, C., Pantuck A., Castellanos, O. Green E., Nguyen K., and D. B. Agus, BMC Cancer, 7:142
• Mechanisms of Emotional Adjustment following Treatment Decision-Making for Prostate Cancer: Conversations, Cognitive Processing, and Coping.  
  Christie,K., Meyerowitz, B., Giedzinska-Simons, A., Gross, M., Agus, D.B, Psycho-Oncology, 18: 508-14
• Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.  
  Gross, M., Ramirez, C., Luthringer, D., Nepomuceno, E., Vollmer, R., Burchette, J., Freedland, S.J, The Prostate, 69:520-7
• Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer (CRPC).  
  Yu E, Massard C, Gross M, Wilding G, Posadas E, Culine S, Carducci MA, Trudel G, Paliwal P, Sternberg C, Clin Canc Res 15:7421-7428
• Androgen Receptor Mutation Detection of Circulating Tumor Cells in Castration Resistant Prostate Cancer.  
  Jiang, Y., Palma, J., Agus, D.B., Wang, Y., Gross, M.E, Clinical Chemistry, 56(9):1492-5
• Show us a sign: the search for “game changing” prostate cancer biomarkers.  
  Quinn, D., Gross, M, Lancet Oncology, 12(3):204-6
• 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ul...  
  Ukimura, O., Desai, M.M., Palmer, S., Valenceria, S., Gross, M., Abreu, A.L., Aron, M., Gill, I.G, J. Urol. 187(3):1080-6
• Body Image Predicts Quality of Life in Men with Prostate Cancer.  
  Taylor-Ford, M., Meyerowitz, B.E., D’Orazio, L.M., Christie,K.M., Gross, M.E., Agus, D.B, Psycho-Oncology
• Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer.  
  Amato, R., Wilding, G., Bubley, G., Trudeau, C., Rivera, V.M.. Agus, D.B. Gross, M, Clin. Genitourin. Cancer 4:299-302
• Androgen receptor and estrogen receptor-beta associates with Gleason score, but not obesity in prostate cancer.  
  Gross, M., Nepomuceno, E., Luthringer, D, Vollmer, R., Burchette, J., Freedland, S, Proc. Amer. Urol. Assoc, Abstract 1618
• A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085).  
  Yu, E., Massard, C., Gross, M., Wilding, G., Posadas, E., Culine, S., Carducci, M. A., Trudel, G., Paliwal, P., Sternberg C, Proc. Amer. Soc. of Clin. Oncol., Abstract 5147
• Join now to see all

Books/Book Chapters

• The Molecular Cancer Handbook. 
  Chapter: Models for Prostate Cancer 
  Jain, A., Vashistha, S., Gross, M., Agus, DEditors: Jörg Haier.Edition 2,
• Drug Management of Prostate Cancer. 
  Chapter: Applications of Proteomics in Prostate Cancer 
  Gross, M., Nepomuceno, E., Agus, DEditors: William Douglas Figg, Sr., Cindy H. Chau, and Eric J.Small, Springer Science + Business Media, New York

Abstracts/Posters

• Androgen receptor and estrogen receptor-beta associates with Gleason score, but not obesity in prostate cancer.
  Mitchell E, American Urological Association, Anaheim, California
• Raloxifene, a selective estrogen receptor modulator, for the treatment of androgen independent prostate cancer (AIPC).
  Cinman, N., Aronson, N., Shazer, R., Nguyen, K.N., Nguyen, H.H.T., Bender, L., Green, L., Gross, M., Kaplan, L.M., Natale, R. B., Agus, D.B, ASCO Molecular Therapeutics Symposium. Abstract #80
• A Proteomic Approach to Identify Whole Proteins Induced by Androgens, Estradiol, and IL-6 in prostate cancer cells.
  Top, I., Katz, J., Damoiseaxu, R., Agus, D., Gross, M, Proc. Amer. Assoc. Cancer Research, Abstract 3095
• Rare mutations of the PIK3CA gene in a number of cancer types and discovery of a PI3KCA pseudogene.
  Muller, C., Miller, W, Gross, M., Walsh, C., Kawamata, N., Koeffler, P, Proc. Amer. Assoc. Cancer Research, Abstract 1016
• A randomized phase II study of ixabepilone or mitoxantrone and prednisone in patients with taxane-refractory hormone refractory prostate cancer.
  Rosenberg, J.E., Kelly, W.K., Michaelson, D., Wilding, G., Hussain, M., Gross, M., Weinberg, V., Small, E.J, Proc. Amer. Soc. of Clin. Oncol, Abstract 4566
• Obesity, Ethnicity, and Surgical Outcomes for Clinically Localized Prostate Cancer.
  Gross, M., Jo, S., Huang, D., Mirocha, J., Shazer, R., Holden, S., Agus, D, Proc. Amer. Soc. of Clin. Oncol, Abstract 9615
• A phase 2 trial of AP23573, an mTOR inhibitor, in patients with taxane-resistant androgen-independent prostate cancer.
  Gross, M.E., Amato, R.J., Mushtaq, M., Wilding, G., Bubley, G., Trudeau, C., Rivera, V.M.. Bedrosian, C.L., Agus, D.B, European Journal of Cancer 4S:112
• Biomarkers and obesity in surgically treated patients with prostate cancer.
  Gross, M., Bharne, A., Nepomuceno, E., Mirocha, J., Ramirez, D., Luthringer, D, Holden, S., Agus, D., Gross, M, Proc. Amer. Soc. of Clin. Oncol, Abstract 14536
• A longitudinal assessment of treatment-related differences in quality of life among prostate cancer patients.
  Giedzinska-Simons, A., Christie,K., Meyerowitz, B., Gross, M., Agus, D.B, Proc. Amer. Soc. of Clin. Oncol, Abstract 15605
• EMD121974 (NSC 707544, cilengitide) in asymptomatic metastatic androgen independent prostate cancer (AIPCa) patients (pts): A randomized trial by the Prostate Cancer C...
  Bradley, D., Dunn, R., Ryan, C., DiPaola, R., Smith, D., Cooney, K., Mathew, P., Gross, M., Colevas, A., Hussain, M, Proc. Amer. Soc. of Clin. Oncol, Abstract 5137
• Health Related Quality of Life Correlates of the Treatment Decision-Making Process of Newly Diagnosed Prostate Cancer Patients.
  Giedzinksa-Simons AS, Christie KM, Meyerowitz BE, Gross M, Agus DB, Society of Behavioral Medicine
• Beta-2-microglobulin: Potential for a therapeutic target expressed in aggressive prostate cancer.
  Mink, S., Kwon G.Y., Luthringer, D.J., Amin, M.B., Agus, D.B. Gross, M, Proc. AACR Annual Meeting, Abstract 3019
• TPI 287, a third-generation taxane, is active and well tolerated as 2nd line therapy after failure of docetaxel in hormone refractory prostate cancer (HRPC).
  Gross, M., Pendergrass, K., Leitner, S., Leichman, G., Pugliese, L., Silberman S, Proc. Amer. Soc. of Clin. Onco, Abstract 16130l
• Cilengitide in asymptomatic metastatic androgen independent prostate cancer (AIPC) patients (pts): A randomized phase II trial.
  Bradley, D. A., Daignault, S., Ryan, C., DiPaola, R.P., Smith, D.C., Mathew P., Gross, M., Chen, A. P., Keller, E. T., Hussain M. H, Proc. Amer. Soc. of Clin. Oncol, Abstract 5144
• Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study.
  Yu, E.Y., Wilding, G., Posadas, E., Gross, M., Culine, S., Massard, C., Hudes, G.R., Cheng, S., Paliwal, P., Sternberg C. N, Proc. Amer. Soc. of Clin. Oncol, Abstract 5156
• Circulating Tumor Cell Enumeration Combined with Gene Expression Analysis and Clinical Variables in Castrate Resistant Prostate Cancer.
  Gross, M, Agus, D, Palma, J., Wang, Y., Jiang, J, AACR Translational Oncology, Abstract B33
• Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC).
  Gross, M. E., Soscia, J., Sakowsky, S., Castellanos, O., Agus D. B, Proc. Amer. Soc. of Clin. Oncol, Abstract 5154154.
• Safety, Efficacy, and Pharmacodynamics of the Iinvestigational Agent TAK-700 in Metastatic Castration-Resistant Prostate Cancer.
  Agus, D.B., Stadler, W.M., Shevrin, D.H., MacVicar, G.R., Hamid, O., Hainsworth, S., Gross, M.E., Wang, J., de Leon, L., MacLean, D., Dreicer, R, Proc. Amer. Soc. of Clin. Oncol, Abstract 4531
• Evaluation of Circulating Tumor Cells in Chemotherapy-naieve Patients with Metastatic Castration-Resistant Prostate Cancer Receiving TAK-700.
  Gross. M., Shevrin, D., Dreicer, R., Trpicchio, W.L., MacLean, D., Webb, I., Agus, D.B, Proc. Eur. Soc. Med. Oncol. Abstract 7.014
• Cell lysis by low power focused acoustic transducer and investigation of acoustic intensity threshold for cytolysis of various cell lines.
  Wang, L., Li, Y.-J., Lin, A., Chen, S.-J., Gross, M., and Kim, E.S, 15th International Conference on Minaturized Systems for Chemistry and Life (MicroTAS 2011), Seattle
• Non-enrichment based method for analysis of androgen receptor expression in circulating tumor cells in patients with metastatic castrate resistant prostate cancer.
  Gross, M.E., Lazar, D., Cho, E.H., Luttgen, M., Metzner, T., Uson, M.L., Torrey, M.L., and Kuhn, P, American Society for Clinical Oncology Genitourinary Conference (ASCO GU 2012), San Francisco, Calif
• Combinatory localize cytolysis with micron precision by acoustic transducer array for fast screening of drug induced cytoskeleton alteration.
  Wang, L., Li, Y.-J., Lin, A., Choe, Y., Gross, M., and Kim, E.S, Proceedings of the 25th International Conference on Micro Electro Mechanical Systems (MEMS 2012), Pa
• Join now to see all

Lectures

• Update on Prostate Cancer. 
  Los Angeles, California, 2007, 2008
• Drug Development Series, Targeted Bone Therapy for Prostate Cancer. 
  UT San Antonio Health Sciences Cente
• Hematology-Oncology Grand Rounds. 
  Cedars Sinai Medical Center, Los Angeles, California
• Update on Prostate Cancer Therapy. 
  USTOO Support Group, Long Beach, California, 2002, 2004
• Targeted Therapy for Prostate Cancer. 
  Wellness Community, Santa Monica, California
• Update on Chemotherapy for Prostate Cancer. 
  CSMC Oncology Grand Rounds, Los Angeles, California
• Prostate Cancer Chemotherapy. 
  Prostate Cancer Research Institute, Los Angeles, California
• Prostate Cancer Overview. 
  Oncology Training Institute, New York, NY
• Clinical Trials for Prostate Cancer. 
  CSMC Oncology Grand Rounds, Los Angeles, California
• Hormonal Therapy for Prostate Cancer. 
  CSMC Endocrinology Grand Rounds, Los Angeles, California
• ASCO 2004 Review: Prostate. 
  CSMC, Los Angeles, California
• Treatment for Rising PSA. 
  CSMC Urology Day, Los Angeles, California
• Laboratory Update on Prostate Cancer. 
  Prostate Cancer National Conference, Washington, D.C
• Bench to Bedside for Prostate Cancer. 
  Wellness Community, Westlake Village, California
• Zone of Proximal Development:What Prostate Oncology Can Learn from Breast Oncology & Related Fields. 
  CSMC Hematology-Oncology Grand Rounds, Los Angeles, California
• Prostate Cancer Patient Education Series: Focus on Advanced Disease. 
  Los Angeles, California
• Novel Therapies for Prostate Cancer. 
  PCRI Regional Conference, Los Angeles, California
• Obesity and Prostate Cancer. 
  CSMC Endocrine Grand Rounds, Los Angeles, California
• Medicine Noon Conference, Prostate Cancer Overview. 
  Resident Teaching Noon Conference, Los Angeles, California
• Join now to see all